Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

OBJECTIVE: This post hoc analysis evaluated the safety and efficacy of open‐label sarilumab in patients with rheumatoid arthritis (RA) who completed the phase III double‐blind ASCERTAIN study (NCT01768572) and switched from intravenous (IV) tocilizumab to subcutaneous (SC) sarilumab, or who continue...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:ACR Open Rheumatol
Main Authors: Emery, Paul, van Hoogstraten, Hubert, Thangavelu, Karthinathan, Mangan, Erin, St John, Gregory, Verschueren, Patrick
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Brief Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7672306/
https://ncbi.nlm.nih.gov/pubmed/33164349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr2.11188
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares